New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:57 EDTRLYPRelypsa price target raised to $41 from $25 at Stifel
Stifel believes that recent data emphasizes the primary role of Relypsa's patiromer in treating patients following the initial abatement of hyperkalemia, and it expects doctors to be impressed by the data. Stifel now expects Relypsa to launch a partnership in Europe and collect 45% royalties there starting in FY17. It keeps a Buy rating on the shares.
News For RLYP From The Last 14 Days
Check below for free stories on RLYP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RLYP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use